| Issue Date |
Title |
Author(s) |
| Feb-2021 |
Camrelizumab Plus Apatinib in Extensive-Stage SCLC (PASSION): A Multicenter, Two-Stage, Phase 2 Trial |
Fan, Yun;Zhao, Jun;Wang, Qiming;Huang, Dingzhi;Li, Xingya;Chen, Jianhua;Fang, Yong;Duan, Jianchun;Zhou, Caicun;Hu, Yanping;Yang, Haihua;Hu, Yi;Zhou, Jianying;Lin, Xiaoyan;Wang, Lifeng;Wang, Zhijie;Xu, Yanjun;Zhang, Tao;Shi, Wei;Zou, Jianjun;Wang, Jie |
| Aug-2020 |
Camrelizumab plus apatinib in extensive-stage small-cell lung cancer (PASSION): A multicenter, two-stage, phase 2 trial |
Wang, Jie;Fan, Yun;Zhao, Jun;Wang, Qiming;Huang, Dingzhi;Li, Xingya;Chen, Jianhua;Fang, Yong;Wang, Zhijie;Zhou, Caicun;Hu, Yanping;Yang, Haihua;Hu, Yi;Zhou, Jianying;Lin, Xiaoyan;Wang, Lifeng;Xu, Yanjun;Li, Hanying |
| Apr-2022 |
The prevalence and real-world therapeutic analysis of Chinese patients with KRAS-Mutant Non-Small Cell lung cancer |
Chen, Hanxiao;Huang, Dingzhi;Lin, Gen;Yang, Xue;Zhuo, Minglei;Chi, Yujia;Zhai, Xiaoyu;Jia, Bo;Wang, Jingjing;Wang, Yuyan;Li, Jianjie;An, Tongtong;Wu, Meina;Wang, Ziping;Zhao, Jun |
| 2007 |
Ramosetron versus ondansetron in the prevention of chemotherapy-induced gastrointestinal side effects: A prospective randomized controlled study |
Shi, Yuankai;He, Xiaohui;Yang, Sheng;Ai, Bin;Zhang, Changgong;Huang, Dingzhi;Dong, Mei;Liu, Peng;Zhou, Shengyu;Han, Xiaohong |
| Jul-2021 |
Results from RATIONALE 303: A global phase 3 study of tislelizumab (TIS) vs docetaxel (TAX) as second- or third-line therapy for patients with locally advanced or metastatic NSCLC. |
Zhou, Caicun;Huang, Dingzhi;Yu, Xinmin;Liu, Yunpeng;Fan, Yun;Shu, Yongqian;Ma, Zhiyong;Wang, Ziping;Cheng, Ying;Wang, Jie;Hu, Sheng;Liu, Zhihua;Dvorkin, Mikhail;Poddubskaya, Elena;Disel, Umut;Akopov, Andrey;Ma, Yiyuan;Wang, Yan;Pan, Zhenyu;Yu, Cunjing;Rivalland, Gareth |
